Overton's rule helps to estimate the penetration of anti-infectives into patients' cerebrospinal fluid

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 979-988

  Djukic, Marija ^a   Munz, Martin ^b   Sörgel, Fritz ^b,c   Holzgrabe, Ulrike ^d   Eiffert, Helmut ^e   Nau, Roland ^a,e  

^a Sleep Laboratory   (Germany)

^b Institute for Biomedical Research   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANILINE; CEFTRIAXONE; DYE; LIPID; LOPINAVIR;

AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; LIPOPHILICITY; MENINGITIS; MOLECULAR WEIGHT; PARTITION COEFFICIENT; PH; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; BIOLOGICAL TRANSPORT, ACTIVE; BRAIN; CEREBROSPINAL FLUID; HUMANS; MENINGES;

EID: 84856068312     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00437-11     Document Type: Article

References (141)

1. Albanese J, et al. 2000. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob. Agents Chemother. 44:1356-1358. (Pubitemid 30228320)
2. Albert F, Bishop-Freudling GB, Vergin H. 1984. Diffusion of tetroxoprim and sulfadiazine in the cerebrospinal fluid of neurosurgery patients. Fortschr. Med. 102:1064-1066. (In German.) (Pubitemid 14019945)
3. Alffenaar JW, et al. 2008. Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis. Antimicrob. Agents Chemother. 52:2293-2295. (Pubitemid 351758586)
4. Alffenaar JW, et al. 2009. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Clin. Infect. Dis. 49:1080-1082.
5. Aller SG, et al. 2009. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718-1722.
6. Andersen NE, Gyring J, Hansen AJ, Laursen H, Siesjo BK. 1989. Brain acidosis in experimental pneumococcal meningitis. J. Cereb. Blood Flow Metab. 9:381-387. (Pubitemid 19134815)
7. AstraZeneca. 2007. Product monograph "Merrem." AstraZeneca, Mississauga, Ontario, Canada.
8. Bakken JS, Bruun JN, Gaustad P, Tasker TC. 1986. Penetration of amoxicillin and potassium clavulanate into the cerebrospinal fluid of patients with inflamed meninges. Antimicrob. Agents Chemother. 30:481-484. (Pubitemid 16017333)
9. Beer R, et al. 2007. Pharmacokinetics of intravenous linezolid in cerebrospinal fluid and plasma in neurointensive care patients with staphylococcal ventriculitis associated with external ventricular drains. Antimicrob. Agents Chemother. 51:379-382. (Pubitemid 46047736)
10. Bellmann R. 2007. Clinical pharmacokinetics of systemically administered antimycotics. Curr. Clin. Pharmacol. 2:37-58. (Pubitemid 46723129)
11. Boffito M, et al. 2003. Protein binding in antiretroviral therapies. AIDS Res. Hum. Retroviruses 19:825-835. (Pubitemid 37215138)
12. Brodie BB, Kurz H, Schanker LS. 1960. The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J. Pharmacol. Exp. Ther. 130:20-25.
13. Capparelli EV, et al. 2005. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19:949-952. (Pubitemid 40834938)
14. Choong E, Dobrinas M, Carrupt PA, Eap CB. 2010.The permeability P-glycoprotein: a focus on enantioselectivity and brain distribution. Expert Opin. Drug Metab. Toxicol. 6:953-965.
15. Chou YW, Yang YH, Chen JH, Kuo CC, Chen SH. 2007. Quantification of meropenem in plasma and cerebrospinal fluid by micellar electrokinetic capillary chromatography and application in bacterial meningitis patients. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 856:294-301.
16. Contrepois A, et al. 1985. Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans. Antimicrob. Agents Chemother. 27:520-524. (Pubitemid 15097652)
17. Craft JC, Feldman WE, Nelson JD. 1979. Clinicopharmacological evaluation of amoxicillin and probenecid against bacterial meningitis. Antimicrob. Agents Chemother. 16:346-352. (Pubitemid 10224030)
18. Dacey RG, Sande MA. 1974. Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives. Antimicrob. Agents Chemother. 6:437-441.
19. Davey PG. 1991. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J. Hosp. Infect. 19(Suppl. A):29-37.
20. Davson H, Welch K, Segal MB. 1987. Physiology and pathophysiology of the cerebrospinal fluid. Churchill Livingstone, London, United Kingdom.
21. Dayan AD. 2003. Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics. Acta Trop. 86:141-159. (Pubitemid 36561365)
22. Dickinson GM, Droller DG, Greenman RL, Hoffman TA. 1981. Clinical evaluation of piperacillin with observations on penetrability into cerebrospinal fluid. Antimicrob. Agents Chemother. 20:481-486. (Pubitemid 12239259)
23. Donald PR, Gent WL, Seifart HI, Lamprecht JH, Parkin DP. 1992. Cerebrospinal fluid isoniazid concentrations in children with tuberculous meningitis: the influence of dosage and acetylation status. Pediatrics 89:247-250.
24. Dudley MN, Levitz RE, Quintiliani R, Hickingbotham JM, Nightingale CH. 1984. Pharmacokinetics of trimethoprim and sulfamethoxazole in serum and cerebrospinal fluid of adult patients with normal meninges. Antimicrob. Agents Chemother. 26:811-814. (Pubitemid 15181369)
25. Dunlop EM, Al-Egaily SS, Houang ET. 1979. Penicillin levels in blood and CSF achieved by treatment of syphilis. JAMA 241:2538-2540. (Pubitemid 9231944)
26. Ehrlich P. 1885. Über das Sauerstoffbedürfnis des Organismus. Eine farbenanalytische Studie. Hirschwald-Verlag, Berlin, Germany.
27. Ellard GA, Humphries MJ, Allen BW. 1993. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis. 148:650-655. (Pubitemid 23263774)
28. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin. Infect. Dis. 40:1333-1341. (Pubitemid 40570245)
29. Felgenhauer K. 1974. Protein size and cerebrospinal fluid composition. Klin. Wochenschr. 52:1158-1164.
30. Friedland IR, Sultan E, Lehr KH, Lenfant B. 1998. Concentrations of cefpirome in cerebrospinal fluid of children with bacterial meningitis after a single intravenous dose. Antimicrob. Agents Chemother. 42:199-201. (Pubitemid 28053355)
31. Friedman CA, Lovejoy FC, Smith AL. 1979. Chloramphenicol disposition in infants and children. J. Pediatr. 95:1071-1077. (Pubitemid 10249813)
32. GlaxoSmithKline. 2008. Trizivir. GlaxoSmithKline Shire Canada, Missauga, Ontario, Canada.
33. Goldmann EE. 1909. Die äußere und innere Sekretion des gesunden und kranken Organismus im Lichte der "vitalen Färbung." Beitr. Klin. Chirurg. 64:192-265.
34. Goldmann EE. 1913. Vitalfärbung am Zentralnervensystem. Abh. Preuß. Akad. Wiss. Phys.-Math. Klasse. 1:1-60.
35. Goncalves-Pereira J, Povoa P. 2011. Antibiotics in critically ill patients - a systematic review of the pharmacokinetics of beta-lactams. Crit. Care 15:R206.
36. Grime JM, Edwards MA, Rudd NC, Unwin PR. 2008. Quantitative visualization of passive transport across bilayer lipid membranes. Proc. Natl. Acad. Sci. U. S. A. 105:14277-14282.
37. Haas DW, et al. 2000. Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin. Pharmacol. Ther. 68:367-374.
38. Hedaya MA, Sawchuk RJ. 1989. Effect of probenecid on the renal and nonrenal clearances of zidovudine and its distribution into cerebrospinal fluid in the rabbit. J. Pharm. Sci. 78:716-722. (Pubitemid 20101916)
39. Hengge UR, Brockmeyer NH, Malessa R, Ravens U, Goos M. 1993. Foscarnet penetrates the blood-brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob. Agents Chemother. 37:1010-1014. (Pubitemid 23141313)
40. Holdiness MR. 1984. Clinical pharmacokinetics of the antituberculosis drugs. Clin. Pharmacokinet. 9:511-544. (Pubitemid 15211649)
41. Hoshino T, Ishiwada N, Kohno Y. 2010. Free concentration and protein-binding ratio of ceftriaxone in cerebrospinal fluid in paediatric patients with purulent meningitis caused by Haemophilus influenzae type b. Int. J. Antimicrob. Agents 35:512-513.
42. Jimenez-Mejias ME, et al. 2002. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Eur. J. Clin. Microbiol. Infect. Dis. 21:212-214.
43. Jung H, Hurtado M, Sanchez M, Medina MT, Sotelo J. 1990. Plasma and CSF levels of albendazole and praziquantel in patients with neurocysticercosis. Clin. Neuropharmacol. 13:559-564.
44. Kanellakopoulou K, et al. 2008. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J. Antimicrob. Chemother. 61:1328-1331. (Pubitemid 351753602)
45. Kawaguchi T, et al. 2000. Roles of hydrophobicity, protein binding and the probenecid-sensitive transport system in the cerebrospinal fluid delivery of nucleoside analogues with anti-viral activity. Biol. Pharm. Bull. 23:979-983. (Pubitemid 30662837)
46. Kuhnen E, Pfeifer G, Frenkel C. 1987. Penetration of fosfomycin into cerebrospinal fluid across non-inflamed and inflamed meninges. Infection 15:422-424. (Pubitemid 18082256)
47. Kuroda M, Kusuhara H, Endou H, Sugiyama Y. 2005. Rapid elimination of cefaclor from the cerebrospinal fluid is mediated by a benzylpenicillin- sensitive mechanism distinct from organic anion transporter 3. J. Pharmacol. Exp. Ther. 314:855-861. (Pubitemid 41043871)
48. Larsson AJ, Walker KJ, Raddatz JK, Rotschafer JC. 1996. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J. Antimicrob. Chemother. 38:589-597. (Pubitemid 26390400)
49. Lebel MH, et al. 1988. Dexamethasone therapy for bacterial meningitis. Results of two double-blind, placebo-controlled trials. N. Engl. J. Med. 319:964-971.
50. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA. 2000. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Antimicrob. Agents Chemother. 44:2173-2175. (Pubitemid 30484445)
51. Levin VA. 1980. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23:682-684. (Pubitemid 11237830)
52. Levitz RE, Dudley MN, Quintiliani R, Mullany LD, Nightingale CH. 1984. Cerebrospinal fluid penetration of trimethoprim-sulphamethoxazole in two patients with gram-negative bacillary meningitis. J. Antimicrob. Chemother. 13:400-401. (Pubitemid 15091253)
53. Lode H, et al. 1990. Quinolone pharmacokinetics and metabolism. J. Antimicrob. Chemother. 26(Suppl. B):41-49. (Pubitemid 20382078)
54. Lopez-Cortes LF, et al. 2000. Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits. Antimicrob. Agents Chemother. 44:756-759. (Pubitemid 30117974)
55. Loscher W, Potschka H. 2005. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98. (Pubitemid 40128029)
56. Loscher W, Potschka H. 2005. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog. Neurobiol. 76:22-76. (Pubitemid 41033402)
57. Lycke J, Andersen O, Svennerholm B, Appelgren L, Dahlof C. 1989. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J. Antimicrob. Chemother. 24:947-954. (Pubitemid 20040555)
58. Lycke J, Malmestrom C, Stahle L. 2003. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob. Agents Chemother. 47:2438-2441. (Pubitemid 36919441)
59. Maniu CV, Hellinger WC, Chu SY, Palmer R, Alvarez-Elcoro S. 2001. Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid. Clin. Infect. Dis. 33:745-748. (Pubitemid 32762954)
60. Markantonis SL, et al. 2009. Penetration of colistin into cerebrospinal fluid. Antimicrob. Agents Chemother. 53:4907-4910.
61. Martin E, Koup JR, Paravicini U, Stoeckel K. 1984. Pharmacokinetics of ceftriaxone in neonates and infants with meningitis. J. Pediatr. 105:475-481. (Pubitemid 14072140)
62. Matsuda T, et al. 2009. LC method for the determination of meropenem in cerebrospinal fluid: application to therapeutic drug monitoring. Chromatographia 69:1031-1034.
63. 14C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study. Antimicrob. Agents Chemother. 43:2855-2861.
64. McEvoy GK. 2002. Anti-infective agents: antivirals: acyclovir, p 527-537. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
65. McEvoy GK. 2002. Anti-infective agents: miscellaneous anti-infectives: co-trimoxazole, p 852-861. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
66. McEvoy GK. 2002. Anti-infective agents: miscellaneous anti-infectives: metronidazole, p 864-875. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
67. McEvoy GK. 2002. Anti-infective agents: miscellaneous β-lactam antibiotics: imipenem and cilastin, p 257-267. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
68. McEvoy GK. 2002. Anti-infective agents: penicillins: amoxicillin and clavulanate, p 388-394. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
69. McEvoy GK. 2002. Anti-infective agents: penicillins: cloxacillin, p 360-362. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
70. McEvoy GK. 2002. Anti-infective agents: sulfonamides: sulfadiazine, p 826-827. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
71. McEvoy GK. 2002. Anti-infective agents: cephalosporines: cefepime, p 154-157. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
72. McEvoy GK. 2002. Anti-infective agents: cephalosporines: cefotaxime, p 1170-1180. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
73. McEvoy GK. 2002. Anti-infective agents: cephalosporines: ceftazidime, p 188-198. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
74. McEvoy GK. 2002. Anti-infective agents: cephalosporines: ceftriaxone, p 207-224. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
75. McEvoy GK. 2002. Anti-infective agents: cephalosporines: cephalosporines general statement, p 129-141. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
76. McEvoy GK. 2002. Anti-infective agents: chloramphenicol: chloramphenicol, p 129-141. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
77. McEvoy GK. 2002. Anti-infective agents: penicillins: aminopenicillins general statement, p 369-384. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
78. McEvoy GK. 2002. Anti-infective agents: urinary anti-infectives: trimethoprim, p 841-844. In McEvoy GK (ed), AHFS drug information. American Society of Health-System Pharmacists, Bethesda, MD.
79. McEvoy GK. 2002. Anti-infective agents: antituberculosis agents: rifampin, p 513-524. In McEvoy GK (ed), AHFS drug information, Bethesda, MD.
80. McNamara PJ, Trueb V, Stoeckel K. 1990. Ceftriaxone binding to human serum albumin. Indirect displacement by probenecid and diazepam. Biochem. Pharmacol. 40:1247-1253. (Pubitemid 20311935)
81. Menichetti F, et al. 1996. High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS. Clin. Infect. Dis. 22:838-840. (Pubitemid 26255605)
82. Miller DS, Bauer B, Hartz AM. 2008. Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol. Rev. 60:196-209. (Pubitemid 351962009)
83. Missner A, Pohl P. 2009. 110 years of the Meyer-Overton rule: predicting membrane permeability of gases and other small compounds. ChemPhysChem 10:1405-1414.
84. Mrestani Y, El-Mokdad N, Rüttinger HH, Neubert R. 1998. Characterization of partitioning behavior of cephalosporins using microemulsion and micellar electrokinetic chromatography. Electrophoresis 19:2895-2899. (Pubitemid 28559914)
85. Muller M, et al. 1997. Relationship between serum and free interstitial concentrations of cefodizime and cefpirome in muscle and subcutaneous adipose tissue of healthy volunteers measured by microdialysis. J. Clin. Pharmacol. 37:1108-1113. (Pubitemid 28076454)
86. Nagata Y, Kusuhara H, Endou H, Sugiyama Y. 2002. Expression and functional characterization of rat organic anion transporter 3 (rOat3) in the choroid plexus. Mol. Pharmacol. 61:982-988. (Pubitemid 34441762)
87. Nagata Y, Kusuhara H, Hirono S, Endou H, Sugiyama Y. 2004. Carrier-mediated uptake of H2-receptor antagonists by the rat choroid plexus: involvement of rat organic anion transporter 3. Drug Metab. Dispos. 32:1040-1047. (Pubitemid 39096066)
88. Nau R, Emrich D, Prange HW. 1993. Inverse correlation between disappearance of intrathecally injected 111In-DTPA from CSF with CSF protein content and CSF-to-serum albumin ratio. J. Neurol.Sci. 115:102-104. (Pubitemid 23090192)
89. Nau R, et al. 1997. Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients. Antimicrob. Agents Chemother. 41:987-991. (Pubitemid 27194173)
90. Nau R, et al. 1994. Kinetics of ofloxacin and its metabolites in cerebrospinal fluid after a single intravenous infusion of 400 milligrams of ofloxacin. Antimicrob. Agents Chemother. 38:1849-1853. (Pubitemid 24250736)
91. Nau R, et al. 1998. Disposition and elimination of meropenem in cerebrospinal fluid of hydrocephalic patients with external ventriculostomy. Antimicrob. Agents Chemother. 42:2012-2016. (Pubitemid 28363085)
92. Nau R, et al. 1996. Cerebrospinal fluid ceftazidime kinetics in patients with external ventriculostomies. Antimicrob. Agents Chemother. 40:763-766. (Pubitemid 26071546)
93. Nau R, et al. 1990. Penetration of ciprofloxacin into the cerebrospinal fluid of patients with uninflamed meninges. J. Antimicrob. Chemother. 25:965-973. (Pubitemid 20212441)
94. Nau R, et al. 1992. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges. J. Antimicrob. Chemother. 29:719-724.
95. Nau R, et al. 1993. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob. Agents Chemother. 37:1518-1524. (Pubitemid 23202383)
96. Nau R, et al. 1993. Netilmicin cerebrospinal fluid concentrations after an intravenous infusion of 400 mg in patients without meningeal inflammation. J. Antimicrob. Chemother. 32:893-896. (Pubitemid 24026590)
97. Nau R, Sorgel F, Eiffert H. 2010. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 23:858-883.
98. Nau R, Sorgel F, Prange HW. 1994. Lipophilicity at pH 7.4 and molecular size govern the entry of the free serum fraction of drugs into the cerebrospinal fluid in humans with uninflamed meninges. J. Neurol. Sci. 122:61-65. (Pubitemid 24073751)
99. Nau R, Zysk G, Thiel A, Prange HW. 1993. Pharmacokinetic quantification of the exchange of drugs between blood and cerebrospinal fluid in man. Eur. J. Clin. Pharmacol. 45:469-475. (Pubitemid 23361948)
100. Norrby SR. 1985. Role of cephalosporins in the treatment of bacterial meningitis in adults. Overview with special emphasis on ceftazidime. Am. J. Med. 79:56-61. (Pubitemid 16238596)
101. Orbach E, Finkelstein A. 1980. The nonelectrolyte permeability of planar lipid bilayer membranes. J. Gen. Physiol. 75:427-436. (Pubitemid 10095839)
102. Overton E. 1900. Studien über die Aufnahme der Anilinfarben durch die lebende Zelle. Jahrb. Wiss. Bot. 34:669-701.
103. Pardridge WM, Sakiyama R, Fierer G. 1983. Transport of propranolol and lidocaine through the rat blood-brain barrier. Primary role of globulin-bound drug. J. Clin. Invest. 71:900-908. (Pubitemid 13163262)
104. Paris MM, et al. 1994. Effect of dexamethasone on therapy of experimental penicillin- and cephalosporin-resistant pneumococcal meningitis. Antimicrob. Agents Chemother. 38:1320-1324. (Pubitemid 24170714)
105. Pea F, et al. 2005. Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery. Antimicrob. Agents Chemother. 49:2554-2557. (Pubitemid 40734505)
106. Pea F, Viale P, Furlanut M. 2005. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet. 44:1009-1034. (Pubitemid 41356389)
107. Pfausler B, et al. 2003. Treatment of staphylococcal ventriculitis associated with external cerebrospinal fluid drains: a prospective randomized trial of intravenous compared with intraventricular vancomycin therapy. J. Neurosurg. 98:1040-1044. (Pubitemid 36460895)
108. Pfausler B, et al. 2004. Concentrations of fosfomycin in the cerebrospinal fluid of neurointensive care patients with ventriculostomy- associated ventriculitis. J. Antimicrob. Chemother. 53:848-852. (Pubitemid 38660290)
109. Quagliarello VJ, Long WJ, Scheld WM. 1986. Morphologic alterations of the blood-brain barrier with experimental meningitis in the rat. Temporal sequence and role of encapsulation. J. Clin. Invest. 77:1084-1095. (Pubitemid 16047126)
110. Raffi F, Taburet AM, Ghaleh B, Huart A, Singlas E. 1993. Penetration of foscarnet into cerebrospinal fluid of AIDS patients. Antimicrob. Agents Chemother. 37:1777-1780. (Pubitemid 23265529)
111. Ricard JD, et al. 2007. Levels of vancomycin in cerebrospinal fluid of adult patients receiving adjunctive corticosteroids to treat pneumococcal meningitis: a prospective multicenter observational study. Clin. Infect. Dis. 44:250-255.
112. Rolinski B, Bogner JR, Sadri I, Wintergerst U, Goebel FD. 1997. Absorption and elimination kinetics of zidovudine in the cerebrospinal fluid in HIV-1-infected patients. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15:192-197.
113. Roussos N, Karageorgopoulos DE, Samonis G, Falagas ME. 2009. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34:506-515.
114. Sachs L. 1986. A guide to statistical methods and to the pertinent literature. Springer-Verlag, Berlin, Germany.
115. Saez-Llorens X, et al. 1995. Prospective randomized comparison of cefepime and cefotaxime for treatment of bacterial meningitis in infants and children. Antimicrob. Agents Chemother. 39:937-940.
116. Schievink HI, Mattie H, Thomeer RT, Van Strijen E. 1993. The passage of cloxacillin into cerebrospinal fluid in the absence of meningitis. Br. J. Clin. Pharmacol. 36:57-60. (Pubitemid 23205314)
117. Shin SG, et al. 1990. Kinetics of isoniazid transfer into cerebrospinal fluid in patients with tuberculous meningitis. J. Korean Med. Sci. 5:39-45.
118. Sjovall J, Bergdahl S, Movin G, Ogenstad S, Saarimaki M. 1989. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 33:1023-1031. (Pubitemid 19168659)
119. Slatter JG, et al. 2001. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. Drug Metab. Dispos. 29:1136-1145. (Pubitemid 32660533)
120. Sorgel F, Kinzig M. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl. A):39-60. (Pubitemid 23078096)
121. Spector R. 1986. Ceftriaxone pharmacokinetics in the central nervous system. J. Pharmacol. Exp. Ther. 236:380-383. (Pubitemid 16184229)
122. Spector R. 2010. Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J. Neurochem. 112:13-23.
123. Stoeckel K, Koup JR. 1984. Pharmacokinetics of ceftriaxone in patients with renal and liver insufficiency and correlations with a physiologic nonlinear protein binding model. Am. J. Med. 77:26-32. (Pubitemid 15209242)
124. Stoeckel K, McNamara PJ, Brandt R, Plozza-Nottebrock H, Ziegler WH. 1981. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin. Pharmacol. Ther. 29:650-657. (Pubitemid 11039305)
125. Takayanagui OM, Bonato PS, Dreossi SA, Lanchote VL. 2002. Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis. Br. J. Clin. Pharmacol. 54:125-130. (Pubitemid 35024935)
126. Tarnaris A, et al. 2011. Rostrocaudal dynamics of CSF biomarkers. Neurochem. Res. 36:528-532.
127. Thea D, Barza M. 1989. Use of antibacterial agents in infections of the central nervous system. Infect. Dis. Clin. North Am. 3:553-570.
128. Tucker RM, et al. 1988. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob. Agents Chemother. 32:369-373.
129. Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. 2011. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin. Pharmacokinet. 50:99-110.
130. Valko K, Nunhuck S, Bevan C, Abraham MH, Reynolds DP. 2003. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm. Sci. 92:2236-2248. (Pubitemid 37356697)
131. van de Waterbeemd H, Smith DA, Jones BC. 2001. Lipophilicity in PK design: methyl, ethyl, futile. J. Comput. Aided Mol. Des. 15:273-286. (Pubitemid 32219940)
132. Vladic A, et al. 2000. Homeostatic role of the active transport in elimination of [3H]benzylpenicillin out of the cerebrospinal fluid system. Life Sci. 67:2375-2385.
133. Warner JF, Perkins RL, Cordero L. 1979. Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess. Arch. Intern. Med. 139:167-169. (Pubitemid 10132264)
134. Weisner B, Bernhardt W. 1978. Protein fractions of lumbar, cisternal, and ventricular cerebrospinal fluid. Separate areas of reference. J. Neurol. Sci. 37:205-214. (Pubitemid 8355357)
135. Wise R. 2003. Maximizing efficacy and reducing the emergence of resistance. J. Antimicrob. Chemother. 51(Suppl. 1):37-42. (Pubitemid 36622103)
136. Wolff M, et al. 1987. Penetration of ciprofloxacin into cerebrospinal fluid of patients with bacterial meningitis. Antimicrob. Agents Chemother. 31:899-902. (Pubitemid 17084047)
137. Wong VK, et al. 1991. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr. Infect. Dis. J. 10:122-125.
138. Yamazaki K, Kanaoka M. 2004. Computational prediction of the plasma protein-binding percent of diverse pharmaceutical compounds. J. Pharm. Sci. 93:1480-1494. (Pubitemid 38725020)
139. Yogev R, Kolling WM, Williams T. 1981. Pharmacokinetic comparison of intravenous and oral chloramphenicol in patients with Haemophilus influenzae meningitis. Pediatrics 67:656-660. (Pubitemid 11061286)
140. Zatz LM, Jernigan TL, Ahumada AJ, Jr. 1982. Changes on computed cranial tomography with aging: intracranial fluid volume. AJNR Am. J. Neuroradiol. 3:1-11. (Pubitemid 12157581)
141. Zettl UK, Lehmitz R, Mix E. 2005. Klinische Liquordiagnostik, vol 2. Walter de Gruyter, Berlin, Germany.